Clinical Trial Update: MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab [Phase 2]

View source ↗

Summary

A Phase 2 study (MoLiMoR) evaluated first-line FOLFIRI-based therapy with or without intermittent cetuximab in colon and rectal adenocarcinoma, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Adenocarcinoma
• Rectal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: TheraOp | Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Status: COMPLETED | Results posted: 2025-06-08